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Abstract
Background: Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks
substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator.
Case presentations: We report a series of four patients, diagnosed with cutaneous T-cell lymphoma, who experienced full
body pruritus recalcitrant to standard therapies. All patients experienced rapid symptom improvement (within days)
following aprepitant treatment.
Conclusion: Aprepitant has been shown in small studies to be efficacious for treating chronic and malignancy-associated
pruritus. Prior studies have shown no change in clinical efficacy of chemotherapeutics with concurrent aprepitant
administration. These cases further demonstrate that aprepitant can be considered as a therapeutic option in
malignancy-associated pruritus and further support the need for larger clinical trials.
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Background
Aprepitant (Emend; Merck & Co Inc) has been approved
for use as an antiemetic in patients receiving chemother-
apy. It blocks the binding of substance P to its receptor,
neurokinin-1, which plays a role in pathways that induce
nausea and vomiting. Recently in the literature, there
have been multiple successful case reports of aprepitant
use for pruritus. We report four cases of successful use
of aprepitant for generalized pruritus in patients
diagnosed with cutaneous T-cell lymphoma (CTCL) and
review the available clinical literature.
Case presentation
A 51-year-old woman presented with a 1.5-year history of
lymphomatoid papulosis and extensive cutaneous anaplas-
tic large cell lymphoma. The patient had experienced
severe full-body itch with the diagnosis of her disease,
which was moderately responsive to prednisone. She had
previously been treated for her lymphoma with metho-
trexate and NB-UVB with no improvement in disease or
itch. PUVA was tried and discontinued because of bullae
development. She subsequently completed eight cycles of
brentuximab, but had disease progression off treatment.
She was then started on a clinical trial with an inhibitor of
program death receptor 1 (PD-1), but was taken off the
trial due to progressive disease. Itch persisted throughout
her disease course. She began treatment with single-agent
gemcitabine 6 weeks prior to the initiation of aprepitant
and had persistent itch and disease with this.
On exam, she had multiple erythematous and skin-
colored papules and plaques on her face, upper extremities,
trunk and neck. She had no lymphadenopathy. Laboratory
findings including serum chemistries, blood urea nitrogen,
complete blood cell count, thyroid and liver function were
normal.
Treatment with oral aprepitant, day 1, 125 mg; day 2,
80 mg; day 3, 80 mg was initiated with cycle 3, day 1 of
gemcitabine chemotherapy (administered days 1, 8 of a
28 day cycle). Her symptoms improved three hours after
aprepitant treatment from 10/10 to 0/10 for five days, but
then her pruritus returned at 4/10 and increased thereafter
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until she took her next aprepitant dose with chemo-
therapy. On weeks where she did not take aprepitant,
days 16–28, she experienced severe pruritus. She
completed three cycles of gemcitabine with minimal
response in her disease. Three weeks after aprepitant
initiation, she underwent electron beam radiation
therapy and began romidepsin. Aprepitant dosing was
adjusted to every other day, with pruritus reaching 5/10
before the next dose and pruritus relief to 0/10 following
every dose. Three months after aprepitant initiation, due
to increased disease burden, brentuximab chemotherapy
and surface conformal brachytherapy were initiated.
Aprepitant dosing was then adjusted to every three days
due to attempt to prolong reduced itch periods, as
insurance coverage was challenging; she continued with
pruritus reduction ranging from 4/10 to 0/10 for 1 year
using this regimen.
Three additional patients with cutaneous T-cell
lymphoma (CTCL) were treated with aprepitant for
pruritus. The clinical findings of these patients are
shown in Table 1.
Discussion
Itch in the oncology patient presents an additional
challenge that may dramatically affect quality of life in those
already facing a cancer diagnosis and adverse effects from
antineoplastic therapies. Pruritus is thought to be a
multifactorial symptom that may be induced by local skin
immune responses as well as global neurological pathways.
Local cutaneous pathways are mediated by itch-
selective C nerve fibers, whose signals are augmented
by local T cells, mast cells, cytokines and neuropep-
tides. The C nerve fibers synapse with second-order
projections, which continue to transmit signals to the
thalamus for processing [1].
Aprepitant, approved for use in chemotherapy-induced
nausea and vomiting in 2003, has been used with increas-
ing frequency for this indication both as a stand-alone
treatment and as part of combination regimens. This
medication is well tolerated. In a systematic review includ-
ing 8740 patients treated with aprepitant, statistically
significant differences in fatigue and hiccups as well as
infections were seen; of note the patients contributing to
increased infections were from a single study where high
doses of dexamethasone were used concomitantly [2, 3].
Aprepitant is a neurokinin-1 (NK1) receptor antagonist
that can cross the blood-brain barrier; it prevents sub-
stance P from binding to its NK1 receptor. Substance P, a
tachykinin neuropeptide, mediates nausea pathways in the
brainstem as well as itch pathways from the skin to spinal
cord [4]. Injected substance P into the skin of non-atopic
patients induces an itch response in normal and inflamed
skin [5]. Atopic dermatitis patients have been observed to
have increased substance P-positive and NK1 receptor-
immunoreactive nerve fibers as compared to healthy
controls [6]. Substance P has been shown to bind NK1
receptors on keratinocytes, which activate mast cell
degranulation and release of cytokines and chemokines
such as histamine, prostaglandin D2 and leukotriene B4,
which mediate itch [7]. NK1 receptors are also present in
rat dorsal horn neurons, which may play a role in neuro-
logic itch [8]. The importance of these neurotransmitters
specifically in oncology patients has not been studied and
their roles require further research.
Pruritus is sometimes a non-specific presenting com-
plaint of underlying malignancy. While this is most often
described with Hodgkin’s disease, it is also reported with
many solid tumors such as those originating in the breast,
gastrointestinal system and liver. In small studies of patients
with non-specific generalized itching, underlying malig-
nancy was found to be the cause of itch in fewer than 10%
of patients [9]. Appropriate assessment of true, diffuse prur-
itus symptoms includes an age and symptom appropriate
malignancy evaluation. The pathophysiology of malignancy
and itch has yet to be clearly elucidated; however, many
mediators have been suggested to play a role. Recent stud-
ies propose that the T-cell dysregulation associated with
Hodgkin’s lymphoma contributes to high rates of pruritus
associated with this malignancy [10] and the cytokines IL-6,
IL-8, and IL-31 may also play roles in lymphoma-associated
or chronic itch [9]. In our reported cases, patients suffered
from cutaneous lymphoma, which unlike pruritus without
a rash, has multiple potential contributors to itch
symptoms. These patients were concurrently treated for
their primary malignancy with variable response. Although
malignancy treatment may also relieve pruritus, in all of
our cases, patients had previously failed conventional
treatments for itch for many months prior. Our cases also
reported pruritus cessation within hours to days after apre-
pitant treatment, in the setting of progressive or persistent
malignancy, suggesting that aprepitant has a direct effect
on symptom relief. Prior reports also suggest that patients
suffered rebound itch upon cessation of aprepitant with
continuation of chemotherapy, suggesting a role for aprepi-
tant’s direct involvement in pruritus relief.
Aprepitant is metabolized through the cytochrome P450
system, specifically CYP3A4. It moderately inhibits
CYP3A4, induces CYP2C9 and possibly affects other
isoenzymes. As such, medication interactions, specifically
with chemotherapeutic drugs metabolized by these en-
zymes should always be considered [11]. However, studies
in patients concurrently treated with aprepitant and doce-
taxel, vinorelbine or cyclophosphamide have not shown
clinically significant decreases in chemotherapeutic serum
concentrations [12].
To date, at least 74 patients in the literature have been
reported to experience pruritus relief with aprepitant
treatment (Table 1). In prospective studies, pruritus relief
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has been reported in 80–91% of patients, suggesting that
aprepitant may be uniquely effective against itch, espe-
cially in patients with symptoms refractory to standard
treatments [13–15]. Because itch pathways have not been
fully elucidated and are likely activated through more than
one process in the oncology patient with inflammatory
skin lesions, deactivating itch likely requires a multi-
faceted approach. With persistence of an inflammatory
malignancy, the trigger of the itch response persists and it
is expected that the itch will recur. In addition, chemo-
therapeutic regimens may result in modified pathways via
effects on the skin and small nerve fibers. When multiple
potential causes of itch exist, combination therapy with
conventional anti-itch agents may be helpful; emollients,
topical steroids, antihistamines, gabapentin, pregabalin,
mirtazapine, ultraviolet light and tricyclic antidepressants
should be considered depending on patient findings,
comorbidities and with consideration of medication inter-
actions. These can be adjusted to bridge non-aprepitant
days and in instances of treatment delays due to medica-
tion access.
In small studies, aprepitant has been shown to be both
safe and effective in treatment of malignancy-associated
and refractory chronic pruritus. In 10 patients with an
atopic diathesis, aprepitant reduced itch >40% in 9/10
patients [13]. Further research is needed to evaluate the
patient population most likely to respond to aprepitant for
pruritus, as it may be a tool for malignancy-associated
itch, as well as in inflammatory conditions associated with
chronic pruritus. However, as demonstrated in our table,
there is significant heterogeneity in dosing regimens and
duration of treatment. Practitioners have prescribed dos-
ing either as 80 mg daily or in a tri-fold pack of 125 mg/
80 mg/80 mg for 3 days to 24 weeks. While further studies
are needed to determine the most effective dosing regi-
men in oncology patients, of the previous reports of six
patients treated with aprepitant 80 mg daily, none experi-
enced a complete response in pruritus. In our patients, we
use tri-fold dosing of 125 mg/80 mg/80 mg, administered
weekly if itch recurs after the first 3 doses. Given that our
patients experienced an increase in pruritus symptoms on
days without aprepitant treatment, until larger dosing
studies are available, we continue treatment while patients
are experiencing relief, as cessation may cause itch to re-
turn to baseline levels.
These cases demonstrate that the use of aprepitant may
be helpful in patients with CTCL who experience pruritus
refractory to conventional treatments. An estimated 66–
88% of CTCL patients report experiencing pruritus with
effects on quality of life [16, 17]. Reports that included
Dermatology Life Quality Index (DLQI) score along with
the visual analogue scale (VAS) demonstrated a high cor-
relation between the two measures. Patients who experi-
enced large improvements in pruritus symptoms by VAS
had similar dramatic decreases in DLQI scores. The VAS
is a commonly used tool for quantifying itch. It has been
validated in patients with chronic itch or pruritic derma-
toses with a high correlation with the numeric rating scale
[18, 19]. Future studies exploring how itch impacts patient
quality of life and the effectiveness of interventions such
as aprepitant should consider patient-reported outcomes.
A disease-specific scale may be of significant use in the
oncology population.
Conclusion
We observed 4 cases of significant pruritus improvement in
CTCL patients treated with aprepitant, supporting that this
modality can be useful in treating some patients with
malignancy-associated itch refractory to conventional treat-
ments. There continues to be a need for larger comparative
effectiveness trials of aprepitant in patients with chronic,
malignancy and treatment-associated itch. Review of the
literature demonstrated discrepancies in dose and timing of
aprepitant regimens as well as outcome measures; pro-
spective studies should evaluate dosing to discern the most
effective administration schedule. Future study is impera-
tive as oncology patients may experience negative impact
on quality of life from treatment refractory pruritus.
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